Evidence map›Paper›PMID 40745064›Full record

ArticleThe EMBO journal2025

Molecular basis of Fab-dependent IgA antibody recognition by gut-bacterial metallopeptidases.

María Ángeles Márquez-Moñino, Ana Martínez Gascueña, Tala Azzam, Andrea Persson, Aitor Manzanares-Gomez, Marina Aguillo-Urarte, Trenton T Brown, Ainhoa Montero-Sagarminaga, Rolf Lood, Andreas Naegeli and 4 more

Abstract read
In one paragraph

Article in The EMBO journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

María Ángeles Márquez-Moñino *Structural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID http://orcid.org/0000-0003-4177-9359
Ana Martínez Gascueña *Structural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID http://orcid.org/0000-0002-6245-5823
Tala AzzamDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8739-7861
Andrea PerssonGenovis AB, Box 790, Lund, 22007, Sweden.
Aitor Manzanares-GomezStructural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain.
Marina Aguillo-UrarteStructural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID http://orcid.org/0009-0001-8307-0885
Trenton T BrownDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Ainhoa Montero-SagarminagaStructural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain.
Rolf LoodGenovis AB, Box 790, Lund, 22007, Sweden.ORCID http://orcid.org/0000-0002-5974-0674
Andreas NaegeliGenovis AB, Box 790, Lund, 22007, Sweden.
Sean R ConnellStructural Biology of Cellular Machines Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain.
Diego E SastreDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-2010-5398
Eric J SundbergDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Beatriz TrastoyStructural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Barakaldo, Spain. beatriz.trastoybello@bio-bizkaia.eus.ORCID http://orcid.org/0000-0002-2178-732X

Funding

Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
Department of health, Government of Basque Country 2024333029Government of Basque Country MOV_2024_1_0005MEC | Agencia Estatal de Investigación (AEI) JDC2022-048996-I/MRRMEC | Agencia Estatal de Investigación (AEI) PID2021-122177NA-I00MEC | Agencia Estatal de Investigación (AEI) PID2021-122705OB-I00MEC | Agencia Estatal de Investigación (AEI) PRE2022-102570MEC | Agencia Estatal de Investigación (AEI) RYC2020-028922NIAID NIH HHS R01 AI149297
6 · The paper itself

Abstract

Immunoglobulin A (IgA) is essential for mucosal immunity and has been implicated in autoimmune diseases, such as IgA nephropathy. Certain pathogenic and commensal bacteria produce IgA proteases that selectively cleave IgA, potentially aiding bacterial colonization as well as suggesting therapeutic avenues for IgA nephropathy. Here, we investigate the substrate specificities of two enzymes of the M64 metallopeptidase family, the IgA protease ThomasA from Thomasclavelia ramosa and BF3526 from Bacteroides fragilis. Our structural, biochemical, and mutagenesis analyses demonstrate that ThomasA cleaves IgA through exclusive recognition of the Fab region. This mechanism is distinct from that of other antibody-specific peptidases, which typically require engagement of the Fc region. In contrast, X-ray crystal structures of BF3526 in complex with substrate and product peptides, combined with enzymology assays, show that this enzyme targets the N-terminus of pre-digested proteins, but does not act on intact IgA. These findings reveal divergent substrate recognition strategies between M64 family members, while providing new structural insights into their conserved catalytic mechanism.

Indexed as

Bacterial ProteinsBacteroides fragilisEubacterialesImmunoglobulin AImmunoglobulin Fab FragmentsMetalloproteasesCrystallography, X-RayHumansModels, MolecularSubstrate SpecificityBacterial ProteinsImmunoglobulin AImmunoglobulin Fab FragmentsMetalloproteasesBacteroidesIgA NephropathyImmunoglobulin APeptidasesThomasclavelia ramosa

Identifiers

PMID40745064
PMCPMC12402451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.